James B. Breitmeyer - Jul 3, 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Jul 3, 2023
Transactions value $
-$18,720
Form type
4
Date filed
7/5/2023, 06:59 PM
Previous filing
Apr 17, 2023
Next filing
Oct 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Tax liability -$17.3K -48K -8.85% $0.36 494K Jul 3, 2023 Direct F1
transaction ONCT Common Stock Tax liability -$1.44K -4.01K -16.75% $0.36 19.9K Jul 3, 2023 By Spouse F1
holding ONCT Common Stock 197K Jul 3, 2023 By Family Trust
holding ONCT Common Stock 733 Jul 3, 2023 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units.